Aktis Oncology Conference Call Summary Company Overview - **Company**: Aktis Oncology - **Focus**: Targeted radiopharmaceuticals aimed at transforming anti-cancer medicines, particularly for patients lacking existing radiopharmaceutical options [3][4] Core Industry Insights - **Radiopharmaceuticals**: The industry is at an inflection point similar to antibody-drug conjugates (ADCs) five years ago, with significant opportunities for new products [4] - **Target Space**: The current market has limited approved medicines, presenting a "white space opportunity" for new entrants [4] Key Programs and Targets - **Lead Program 1189 (Nectin-4)**: - **Target**: Nectin-4, expressed in various cancers including bladder, breast, lung, cervical, head and neck, and colorectal cancers [18] - **Clinical Validation**: Supported by existing data from PADCEV, a validated treatment for bladder cancer [19] - **Patient Impact**: Aims to provide a radiopharmaceutical option for large patient populations currently without one [18][19] - **Second Program 2519 (B7-H3)**: - **Target**: B7-H3, expressed in lung and prostate cancers, among others [36] - **Competitive Landscape**: While there are existing ADCs targeting B7-H3, Aktis aims to differentiate with a unique isotope (Actinium-225) and a non-overlapping toxicity profile [36][37] Clinical Development and Data - **Imaging Data**: Initial human imaging data for both programs showed high tumor uptake and favorable dosimetry profiles, suggesting a strong therapeutic index [27][29] - **Phase 1b Studies**: Ongoing dose escalation studies for both programs, with updates expected throughout the year [32][38] Supply Chain and Manufacturing - **End-to-End Supply Chain**: Aktis has developed its own supply chain capabilities, including a GMP manufacturing facility expected to open by the end of the year [10][11] - **Actinium Supply**: Multiple supply deals in place to ensure a robust supply of Actinium-225 [15] Partnerships and Collaborations - **Collaboration with Eli Lilly**: Focused on discovery capabilities for novel miniprotein radioconjugates, with successful milestone achievements ahead of schedule [12][13] - **Business Development Strategy**: Emphasis on retaining economic rights to lead programs while exploring partnerships that enhance shareholder value [46] Financial Position - **IPO Proceeds**: Raised $340 million in net proceeds from the IPO, with a cash runway projected into 2029, supporting ongoing clinical development [49][50] Conclusion - **Strategic Positioning**: Aktis Oncology is well-positioned in the radiopharmaceutical space with a strong pipeline, innovative technology, and a solid financial foundation, aiming to address significant unmet needs in cancer treatment [16][50]

Aktis Oncology FY Conference Summary Company Overview - **Company**: Aktis Oncology (NasdaqGS:AKTS) - **Industry**: Targeted radiopharmaceuticals, specifically in oncology - **Focus**: Development of novel radiopharmaceuticals targeting various cancer types beyond current limitations Core Insights and Arguments - **Market Potential**: The radiopharmaceutical category is approaching an inflection point with significant clinical and commercial validation, exemplified by Pluvicto being the best-launching oncology drug in a decade since Ibrance [2][20] - **Target Expansion**: Aktis aims to expand the benefits of radiopharmaceuticals to additional targets beyond the current focus on PSMA and SSTR2, which are limited to specific cancer types [2][3] - **Lead Programs**: Aktis has two lead programs: - **AKY-1189**: Targets Nectin-4 - **AKY-2519**: Targets B7-H3 - Both programs are expected to provide multi-indication and multi-disease area opportunities, potentially leading to large blockbuster drugs [4][20] - **Clinical Development**: The company is focused on generating additional clinical data over the next 1-2 years to support the advancement of these lead programs [5][19] - **Manufacturing and Supply Chain**: Aktis is building its own manufacturing facility to enhance control over the end-to-end supply chain for radiopharmaceuticals, which is currently functioning well for ongoing Phase 1b studies [6][26] Additional Important Content - **Pipeline and Technology**: Aktis has a robust pipeline beyond the lead programs, with ongoing development of additional agents and a focus on generative AI design to enhance target discovery [14][29] - **Market Size Projections**: The therapeutic segment of radiopharmaceuticals is projected to reach $6 billion-$9 billion by the end of the decade, with potential expansion to a $25 billion-$35 billion market, and upside to $60 billion depending on the number of tumor types targeted [20] - **Patient Population Expansion**: The company aims to extend the benefits of radiopharmaceuticals to a broader patient population, including those with bladder, breast, lung, and other cancers, moving beyond the current focus on prostate and rare GI tumors [22][23] - **Advisory Board Insights**: Feedback from advisory boards suggests a preference for earlier lines of treatment rather than following traditional chemotherapy, indicating a potential shift in treatment paradigms [61][64] - **Team Expertise**: The leadership team at Aktis has significant experience, with a combined history of 14 FDA approvals, enhancing confidence in the company's capabilities [27][28] Conclusion Aktis Oncology is positioned at a pivotal moment in the radiopharmaceutical industry, with innovative approaches to expand treatment options for cancer patients. The company's focus on novel targets, robust clinical development, and strategic manufacturing capabilities highlight its potential for significant impact in oncology.

Maximizing the Impact of Radiopharmaceuticals TD Cowen 46th Annual Healthcare Conference March 2026 1 Disclaimer Information in this presentation and the accompanying oral presentation contains forward-looking statements within the meaning of the Private Securities Litigation Act of 1995 that involve substantial risks and uncertainties about Aktis Oncology and the industry in which Aktis Oncology operates, including statements regarding the initiation, timing, progress, results and costs of Aktis Oncology's ...

Company Overview - Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing technologies [4] - The company's most advanced program, AKY-1189, targets Nectin-4 and has multi-indication potential across various tumor types, including locally advanced or metastatic urothelial cancer, breast cancer, non-small cell lung cancer, colorectal cancer, cervical cancer, and head and neck cancer [4] - Aktis' second pipeline program, AKY-2519, targets B7-H3 expressing tumors, including prostate and lung cancers [4] Technology and Innovation - Aktis has developed a proprietary, isotope-agnostic miniprotein radioconjugate platform designed to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors [3] - The therapeutic miniprotein radioconjugates maximize anti-cancer activity through high penetration, internalization, and retention in cancer cells while clearing quickly from normal organs and tissues [3] - The platform allows clinicians to visualize and verify target engagement with imaging isotopes prior to exposure to therapeutic radioisotopes, addressing unmet needs in solid tumors [3] Upcoming Events - Matthew Roden, Ph.D., President and CEO of Aktis Oncology, will present at the TD Cowen 46 Annual Health Care Conference on March 3, 2026, at 1:10 p.m. ET in Boston, MA [2] - He will also present at the Leerink Partners Global Healthcare Conference on March 9, 2026, at 1:40 p.m. ET in Miami, FL [2] - A live webcast of the presentations will be available on the Investors section of the Aktis website, with an archived replay accessible for approximately 90 days [2]

Core Viewpoint - Aktis Oncology, Inc. has received Fast Track designation from the U.S. FDA for its drug AKY-1189, aimed at treating adult patients with locally advanced or metastatic urothelial cancer who have progressed after prior systemic therapies [1][7] Group 1: Fast Track Designation - Fast Track designation is intended to expedite the development and review of drugs for serious conditions, allowing for more frequent interactions with the FDA and the possibility of rolling submissions for Biologics License Applications [2] - The designation provides Aktis Oncology a unique opportunity to collaborate closely with the FDA to expedite the development of AKY-1189, addressing an unmet medical need in urothelial cancer treatment [3] Group 2: Clinical Trials and Development - Aktis is conducting a multi-site Phase 1b clinical trial (NCT07020117) for AKY-1189, which includes patients with locally advanced or metastatic urothelial cancer and other Nectin-4 expressing tumors [3] - Preliminary results from Part 1 of the trial are expected to be presented in the first quarter of 2027 [3] Group 3: Technology and Pipeline - Aktis has developed a proprietary miniprotein radioconjugate platform that selectively delivers radioisotopes to targeted tumors, maximizing anti-cancer activity while minimizing exposure to normal tissues [4] - The company’s pipeline includes AKY-1189 targeting Nectin-4 and AKY-2519 targeting B7-H3, with potential applications across various tumor types [5]

Group 1 - A beneficial owner has been increasing their stake in the insurance giant W.R. over the past week [1]

Core Insights - Aktis Oncology, Inc. is a clinical-stage oncology company focused on developing innovative cancer treatments, aiming to significantly impact the biotech sector [1] - The company recently completed its initial public offering (IPO), which is the first sizable offering of 2026, highlighting its growth potential and strategic positioning within the biotech industry [3] IPO Details - Aktis Oncology's IPO involved offering 17.65 million shares at $18 each, with an upsized offering that included an additional 2.65 million shares purchased by underwriters, bringing total gross proceeds to approximately $365.4 million [2] - The shares began trading on the Nasdaq Global Select Market under the ticker symbol "AKTS" on January 9, 2026 [2] Market Performance - As of the latest trading, AKTS is priced at $20.56, reflecting a slight decrease of 1.20% or $0.25, with a daily trading range between $19.69 and $21.43 [3] - Over the past year, the stock has seen a high of $29.16 and a low of $19.02, with a current market capitalization of approximately $1.08 billion and a trading volume of 234,338 shares on the NASDAQ exchange [3]

Core Insights - The article discusses the potential of recent IPOs, particularly in the biotechnology sector, highlighting that some may offer significant long-term investment opportunities despite their perceived risks [3][10] - Aktis Oncology, a company specializing in radiopharmaceuticals, recently went public and aims for long-term success in the market [8][10] Company Overview - Aktis Oncology is the first biotech IPO of 2026, raising $318 million, with $100 million in backing from Eli Lilly [10] - The company has a current market cap of $3.34 billion and focuses on developing radiopharmaceuticals for the treatment and diagnosis of various ailments, including cancer [10][11] Industry Context - The article emphasizes the importance of radiopharmaceuticals within nuclear medicine, which utilizes radioactive drugs for diagnostics and treatment [11] - It contrasts the perception of IPOs as high-risk ventures by providing examples of successful companies that have gone public, suggesting that conservative investors should consider these opportunities [7][10]

Core Viewpoint - Aktis Oncology, Inc. has successfully closed its upsized initial public offering (IPO) of 17,650,000 shares at a price of $18.00 per share, with additional shares bringing total gross proceeds to approximately $365.4 million [1]. Company Overview - Aktis Oncology is a clinical-stage oncology company focused on targeted radiopharmaceuticals aimed at large patient populations, including those not served by existing technologies [4]. - The company's advanced pipeline program targets Nectin-4, utilizing a miniprotein radioconjugate platform designed to deliver radioisotopes selectively to tumors while minimizing side effects [4]. - Aktis' platform is isotope-agnostic, allowing for visualization and verification of target engagement with imaging isotopes before therapeutic exposure [4]. - The company has a strategic collaboration with Eli Lilly and Company to develop novel radioconjugates beyond its proprietary pipeline [4]. IPO Details - The IPO was completed on January 12, 2026, with the underwriters fully exercising their option to purchase an additional 2,647,500 shares, expected to close on January 14, 2026 [1]. - The total gross proceeds from the IPO, including the additional shares, are anticipated to be around $365.4 million before deducting underwriting discounts and commissions [1]. - Aktis' common stock began trading on the Nasdaq Global Select Market under the ticker symbol "AKTS" on January 9, 2026 [1].

Group 1: IPO Highlights - Aktis Oncology led the week with a large IPO, raising $318 million at a valuation of $1 billion, focusing on α-radiopharmaceuticals for solid tumors [1] - Buda Juice completed its IPO at the lower end of its price range, raising $20 million with a market cap of $95 million, emphasizing its "super fresh" juice category [2] - Atlas Critical Minerals also completed its IPO at the lower end, raising $10 million with a market cap of $40 million, focusing on mineral exploration in Brazil [2] Group 2: SPAC Activity - Five SPACs completed their IPOs, including Lafayette Digital Acquisition and Bleichroeder Acquisition II, each raising $250 million, targeting financial services and technology sectors [3] - Other SPACs like Art Technology Acquisition and Soren Acquisition raised $220 million and $150 million respectively, focusing on technology and healthcare [3] Group 3: Upcoming IPO Filings - Six companies filed for IPOs, including Brazilian digital bank PicS seeking $500 million and discount furniture retailer Bobs Discount Furniture aiming for $400 million [5] - Other notable filings include Forgent Power Solutions for $200 million and Eikon Therapeutics for $100 million, both in the healthcare sector [5] Group 4: Market Outlook - The IPO market is expected to be quiet in the upcoming week after the recent large IPO, with smaller issuers potentially joining the market [6] - Several large companies that have submitted IPO applications remain eligible to go public soon, including EquipmentShare.com and Motive Technologies [7]